{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274216","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.141136+00:00","generated_at":"2026-05-16T22:27:59.838067+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spruce Q3 net loss $8.2M; FDA BTD for TA-ERT; $50M placement; BLA on track Q1 2026","bullets":["FDA granted Breakthrough Therapy Designation for TA-ERT (MPS IIIB); BLA submission on track for Q1 2026.","Completed $50M private placement in Oct 2025; cash plus proceeds expected to fund ops into Q4 2026.","Q3 2025 net loss $8.2M vs $8.7M YoY; R&D $5.0M (down 24% YoY) due to tildacerfont program cessation.","Cash $10.7M at Sep 30, 2025; common shares 563,491 pre-placement; Oct placement added 502,181 shares and 233,144 prefunded warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274216","json":"https://secwatch.observer/filing/0001193125-25-274216.json","markdown":"https://secwatch.observer/filing/0001193125-25-274216.md","text":"https://secwatch.observer/filing/0001193125-25-274216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000119312525274216/0001193125-25-274216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000119312525274216/sprb-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:27:59.838067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}